Eran Ovadya Email
Chief Financial Officer . NurExone Biologic (OTCQBNRXBF) (TSXV NRX) (FSE J90)
How to contact Eran Ovadya
Join and see Eran's contact info for free!Current Roles
Employees:
28Revenue:
$5.3MAbout
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System.\nThe breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.NurExone Biologic (OTCQBNRXBF) (TSXV NRX) (FSE J90) Address
Haifa, null
IL